메뉴 건너뛰기




Volumn 113, Issue 1, 2009, Pages 56-64

Paliperidone extended-release for schizophrenia: Effects on symptoms and functioning in acutely ill patients with negative symptoms

Author keywords

Functioning; Negative symptoms; Paliperidone ER; Schizophrenia

Indexed keywords

PALIPERIDONE; PLACEBO;

EID: 67649850363     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.05.021     Document Type: Article
Times cited : (29)

References (34)
  • 1
    • 33744464516 scopus 로고    scopus 로고
    • A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia
    • Alvarez E., Ciudad A., Olivares J.M., Bousono M., and Gomez J.C. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J. Clin. Psychopharmacol. 26 3 (2006) 238-249
    • (2006) J. Clin. Psychopharmacol. , vol.26 , Issue.3 , pp. 238-249
    • Alvarez, E.1    Ciudad, A.2    Olivares, J.M.3    Bousono, M.4    Gomez, J.C.5
  • 2
    • 33750517755 scopus 로고    scopus 로고
    • Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form
    • Conley R., Gupta S.K., and Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr. Med. Res. Opin. 22 10 (2006) 1879-1892
    • (2006) Curr. Med. Res. Opin. , vol.22 , Issue.10 , pp. 1879-1892
    • Conley, R.1    Gupta, S.K.2    Sathyan, G.3
  • 3
    • 0030980659 scopus 로고    scopus 로고
    • The varied outcomes of schizophrenia
    • Davidson L., and McGlashan T.H. The varied outcomes of schizophrenia. Can. J. Psychiatry 42 1 (1997) 34-43
    • (1997) Can. J. Psychiatry , vol.42 , Issue.1 , pp. 34-43
    • Davidson, L.1    McGlashan, T.H.2
  • 4
    • 34249275309 scopus 로고    scopus 로고
    • Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study
    • Davidson M., Emsley R., Kramer M., Ford L., Pan G., Lim P., and Eerdekens M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr. Res. 93 1-3 (2007) 117-130
    • (2007) Schizophr. Res. , vol.93 , Issue.1-3 , pp. 117-130
    • Davidson, M.1    Emsley, R.2    Kramer, M.3    Ford, L.4    Pan, G.5    Lim, P.6    Eerdekens, M.7
  • 5
    • 33646680982 scopus 로고    scopus 로고
    • Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone
    • Gharabawi G.M., Lasser R.A., Bossie C.A., Zhu Y., and Amador X. Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. Int. Clin. Psychopharmacol. 21 4 (2006) 233-240
    • (2006) Int. Clin. Psychopharmacol. , vol.21 , Issue.4 , pp. 233-240
    • Gharabawi, G.M.1    Lasser, R.A.2    Bossie, C.A.3    Zhu, Y.4    Amador, X.5
  • 6
    • 26444444254 scopus 로고    scopus 로고
    • Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy
    • Greenwood K.E., Landau S., and Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr. Bull. 31 4 (2005) 910-921
    • (2005) Schizophr. Bull. , vol.31 , Issue.4 , pp. 910-921
    • Greenwood, K.E.1    Landau, S.2    Wykes, T.3
  • 7
    • 0000238671 scopus 로고
    • Clinical global impressions
    • Revised, 1976 edn, Rockville, Maryland: U.S. Department of Health and Human Services
    • Guy, W., 1976. 'Clinical global impressions', ECDEU Assessment Manual for Psychopharmacology (Revised, 1976 edn.; Rockville, Maryland: U.S. Department of Health and Human Services), 218-222.
    • (1976) ECDEU Assessment Manual for Psychopharmacology , pp. 218-222
    • Guy, W.1
  • 9
    • 67649851025 scopus 로고    scopus 로고
    • Invega, P.I. 2007. Janssen, L.P. Titusville, NJ.
    • Invega, P.I. 2007. Janssen, L.P. Titusville, NJ.
  • 10
    • 33846590147 scopus 로고    scopus 로고
    • Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial
    • Kane J., Canas F., Kramer M., Ford L., Gassmann-Mayer C., Lim P., and Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr. Res. 90 1-3 (2007) 147-161
    • (2007) Schizophr. Res. , vol.90 , Issue.1-3 , pp. 147-161
    • Kane, J.1    Canas, F.2    Kramer, M.3    Ford, L.4    Gassmann-Mayer, C.5    Lim, P.6    Eerdekens, M.7
  • 11
    • 0023606101 scopus 로고
    • The positive and negative syndrome scale (PANSS) for schizophrenia
    • Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
    • (1987) Schizophr. Bull. , vol.13 , pp. 261-276
    • Kay, S.R.1    Fiszbein, A.2    Opler, L.A.3
  • 12
    • 33748743350 scopus 로고    scopus 로고
    • Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning
    • Kinon B.J., Noordsy D.L., Liu-Seifert H., Gulliver A.H., Ascher-Svanum H., and Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J. Clin. Psychopharmacol. 26 5 (2006) 453-461
    • (2006) J. Clin. Psychopharmacol. , vol.26 , Issue.5 , pp. 453-461
    • Kinon, B.J.1    Noordsy, D.L.2    Liu-Seifert, H.3    Gulliver, A.H.4    Ascher-Svanum, H.5    Kollack-Walker, S.6
  • 15
    • 33846235456 scopus 로고    scopus 로고
    • Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study
    • Kramer M., Simpson G., Maciulis V., Kushner S., Vijapurkar U., Lim P., and Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 27 1 (2007) 6-14
    • (2007) J. Clin. Psychopharmacol. , vol.27 , Issue.1 , pp. 6-14
    • Kramer, M.1    Simpson, G.2    Maciulis, V.3    Kushner, S.4    Vijapurkar, U.5    Lim, P.6    Eerdekens, M.7
  • 16
    • 33749496746 scopus 로고    scopus 로고
    • The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial
    • Lecrubier Y., Quintin P., Bouhassira M., Perrin E., and Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatry Scand. 114 5 (2006) 319-327
    • (2006) Acta Psychiatry Scand. , vol.114 , Issue.5 , pp. 319-327
    • Lecrubier, Y.1    Quintin, P.2    Bouhassira, M.3    Perrin, E.4    Lancrenon, S.5
  • 17
    • 33947713524 scopus 로고    scopus 로고
    • A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia
    • Lindenmayer J.P., Khan A., Iskander A., Abad M.T., and Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J. Clin. Psychiatry 68 3 (2007) 368-379
    • (2007) J. Clin. Psychiatry , vol.68 , Issue.3 , pp. 368-379
    • Lindenmayer, J.P.1    Khan, A.2    Iskander, A.3    Abad, M.T.4    Parker, B.5
  • 18
    • 0031431410 scopus 로고    scopus 로고
    • The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials
    • Marder S.R., Davis J.M., and Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 58 12 (1997) 538-546
    • (1997) J. Clin. Psychiatry , vol.58 , Issue.12 , pp. 538-546
    • Marder, S.R.1    Davis, J.M.2    Chouinard, G.3
  • 19
    • 36048941530 scopus 로고    scopus 로고
    • Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study
    • Marder S.R., Kramer M., Ford L., Eerdekens E., Lim P., Eerdekens M., and Lowy A. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol. Psychiatry 62 12 (2007) 1363-1370
    • (2007) Biol. Psychiatry , vol.62 , Issue.12 , pp. 1363-1370
    • Marder, S.R.1    Kramer, M.2    Ford, L.3    Eerdekens, E.4    Lim, P.5    Eerdekens, M.6    Lowy, A.7
  • 20
    • 45249095185 scopus 로고    scopus 로고
    • Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies
    • Meltzer H.Y., Bobo W.V., Nuamah I.F., Lane R., Hough D., Kramer M., and Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J. Clin. Psychiatry 60 5 (2008) 817-829
    • (2008) J. Clin. Psychiatry , vol.60 , Issue.5 , pp. 817-829
    • Meltzer, H.Y.1    Bobo, W.V.2    Nuamah, I.F.3    Lane, R.4    Hough, D.5    Kramer, M.6    Eerdekens, M.7
  • 21
    • 14844321950 scopus 로고    scopus 로고
    • Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up
    • Milev P., Ho B.C., Arndt S., and Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 162 3 (2005) 495-506
    • (2005) Am. J. Psychiatry , vol.162 , Issue.3 , pp. 495-506
    • Milev, P.1    Ho, B.C.2    Arndt, S.3    Andreasen, N.C.4
  • 22
    • 0035676596 scopus 로고    scopus 로고
    • Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia
    • Moller H.J. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 251 5 (2001) 217-224
    • (2001) Eur. Arch. Psychiatry Clin. Neurosci. , vol.251 , Issue.5 , pp. 217-224
    • Moller, H.J.1
  • 23
    • 0028946201 scopus 로고
    • A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study
    • Moller H.J., Muller H., Borison R.L., Schooler N.R., and Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur. Arch. Psychiatry Clin. Neurosci. 245 1 (1995) 45-49
    • (1995) Eur. Arch. Psychiatry Clin. Neurosci. , vol.245 , Issue.1 , pp. 45-49
    • Moller, H.J.1    Muller, H.2    Borison, R.L.3    Schooler, N.R.4    Chouinard, G.5
  • 24
    • 0034022621 scopus 로고    scopus 로고
    • Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning
    • Morosini P.L., Magliano L., Brambilla L., Ugolini S., and Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatry Scand. 101 4 (2000) 323-329
    • (2000) Acta Psychiatry Scand. , vol.101 , Issue.4 , pp. 323-329
    • Morosini, P.L.1    Magliano, L.2    Brambilla, L.3    Ugolini, S.4    Pioli, R.5
  • 25
    • 54049089510 scopus 로고    scopus 로고
    • Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia
    • Nasrallah H., Morosini P., and Gagnon D.D. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 161 2 (2008) 213-224
    • (2008) Psychiatry Res. , vol.161 , Issue.2 , pp. 213-224
    • Nasrallah, H.1    Morosini, P.2    Gagnon, D.D.3
  • 26
    • 33646698646 scopus 로고    scopus 로고
    • Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study
    • Olie J.P., Spina E., Murray S., and Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int. Clin. Psychopharmacol. 21 3 (2006) 143-151
    • (2006) Int. Clin. Psychopharmacol. , vol.21 , Issue.3 , pp. 143-151
    • Olie, J.P.1    Spina, E.2    Murray, S.3    Yang, R.4
  • 27
    • 64249129738 scopus 로고    scopus 로고
    • Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia
    • Patrick D.L., Burns T., Morosini P., Rothman M., Gagnon D.D., Wild D., and Adriaenssen I. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr. Med. Res. Opin. 25 2 (2009) 325-338
    • (2009) Curr. Med. Res. Opin. , vol.25 , Issue.2 , pp. 325-338
    • Patrick, D.L.1    Burns, T.2    Morosini, P.3    Rothman, M.4    Gagnon, D.D.5    Wild, D.6    Adriaenssen, I.7
  • 28
    • 0038826191 scopus 로고    scopus 로고
    • Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia
    • Pickar D., and Bartko J.J. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. Am. J. Psychiatry 160 6 (2003) 1133-1138
    • (2003) Am. J. Psychiatry , vol.160 , Issue.6 , pp. 1133-1138
    • Pickar, D.1    Bartko, J.J.2
  • 32
    • 11144311888 scopus 로고    scopus 로고
    • Quetiapine has a direct effect on the negative symptoms of schizophrenia
    • Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum. Psychopharmacol. 19 8 (2004) 559-563
    • (2004) Hum. Psychopharmacol. , vol.19 , Issue.8 , pp. 559-563
    • Tandon, R.1
  • 33
    • 0031003781 scopus 로고    scopus 로고
    • Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
    • Tollefson G.D., and Sanger T.M. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry 154 4 (1997) 466-474
    • (1997) Am. J. Psychiatry , vol.154 , Issue.4 , pp. 466-474
    • Tollefson, G.D.1    Sanger, T.M.2
  • 34
    • 56849096505 scopus 로고    scopus 로고
    • Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
    • Turkoz I., Bossie C.A., Dirks B., and Canuso C.M. Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. Neuropsychiatr. Dis. Treat. 4 5 (2008) 949-958
    • (2008) Neuropsychiatr. Dis. Treat. , vol.4 , Issue.5 , pp. 949-958
    • Turkoz, I.1    Bossie, C.A.2    Dirks, B.3    Canuso, C.M.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.